Skip to main content
Betty Hamilton, MD, Oncology, Cleveland, OH, Cleveland Clinic

BettyKyHamiltonMD

Oncology Cleveland, OH

Hematologic Oncology

Assistant Professor, Medicine, Case Western Reserve U SOM

Dr. Hamilton is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Hamilton's full profile

Already have an account?

Education & Training

  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2010 - 2013
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Internal Medicine, 2006 - 2009
  • University of Chicago Division of the Biological Sciences The Pritzker School of Medicine
    University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2006

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2010 - 2024
  • PA State Medical License
    PA State Medical License 2006 - 2010
  • American Board of Internal Medicine Medical Oncology
  • American Board of Internal Medicine Hematology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Effect of Bone Marrow CD34+Cells and T-cell Subsets on Clinical Outcomes After Myeloablative Allogeneic Hematopoietic Cell Transplantation  
    Deepa Jagadeesh, Matt Kalaycio, Brian Bolwell, Betty K Hamilton, Brian Hill, Brad Pohlman, Robert Dean, Navneet S Majhail, Sagar S Patel, Rabi Hanna, Aaron T Gerds, Ro..., Nature

Abstracts/Posters

  • Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-Azacytidine
    Betty K. Hamilton, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis
    Betty K. Hamilton, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies
    Betty K. Hamilton, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Clinical Management of Myeloid Malignancies: The Coming of Age of Targeted Therapies 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes: On Behalf of the CIBMTR Ch... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Risk Factors for Mortality in Day +100 Survivors of Allogeneic HCT
    Risk Factors for Mortality in Day +100 Survivors of Allogeneic HCTJune 12th, 2018
  • How All Caregivers — Clinical and Nonclinical — Play a Role in Quality and Safety
    How All Caregivers — Clinical and Nonclinical — Play a Role in Quality and SafetyMarch 30th, 2018
  • ASH 2018: Dec 1-4
    ASH 2018: Dec 1-4December 1st, 2017
  • Join now to see all

Hospital Affiliations